Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conivaptan (Yamanouchi).

Alberto Martinez-Castelao1

  • 1Hospital Bellvitge CSUB, University of Barcelona, Spain. 9349amc@webcmb.comb.es

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic inflammatory profiles are associated with long-term kidney failure and patient mortality in chronic kidney disease.

Clinical kidney journal·2026
Same author

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.

Journal of clinical medicine·2025
Same author

Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.

Nefrologia·2025
Same author

Risk factors for progression in patients with KDOQI stage 3 Chronic Kidney Disease (PROGRESER study).

Nefrologia·2024
Same author

The long-term effect of a lung-ultrasound intervention on the risk for death, heart failure and myocardial infarction in dialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023
Same author

Diabetes Mellitus and Diabetic Kidney Disease: The Future Is Already Here.

Journal of clinical medicine·2023
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Conivaptan, a vasopressin antagonist, is being developed for heart failure, edema, and hyponatremia. Clinical trials are ongoing, with projected launches anticipated between 2003 and 2005.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Conivaptan is an orally active vasopressin V1A and V2 antagonist.
  • It is being developed for potential treatment of heart failure, edema, and hyponatremia.

Purpose of the Study:

  • To summarize the development status and market projections for conivaptan.

Main Methods:

  • Review of clinical trial phases (II and III) and regulatory milestones.
  • Analysis of market predictions from financial institutions.

Main Results:

  • Conivaptan has undergone Phase II and III trials for heart failure and hyponatremia in various regions.
  • Licensing agreements and cancellations have impacted its development path.
  • Projected launch dates for hyponatremia range from 2003 to 2005.

Related Experiment Videos

  • Peak annual sales were estimated at $50 million for hyponatremia and $300 million for heart failure.

    • Conclusions:

    • Conivaptan's development for cardiovascular conditions is progressing through clinical trials.
    • Market entry is anticipated in the mid-2000s, with significant sales potential projected.